These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
82 related articles for article (PubMed ID: 10547433)
1. The immunogenicity in humans of a botulinum type F vaccine. Montgomery VA; Makuch RS; Brown JE; Hack DC Vaccine; 1999 Nov; 18(7-8):728-35. PubMed ID: 10547433 [TBL] [Abstract][Full Text] [Related]
2. Antibody response to a delayed booster dose of anthrax vaccine and botulinum toxoid. Pittman PR; Hack D; Mangiafico J; Gibbs P; McKee KT; Friedlander AM; Sjogren MH Vaccine; 2002 May; 20(16):2107-15. PubMed ID: 11972980 [TBL] [Abstract][Full Text] [Related]
3. Alternative vaccination against equine botulism (BoNT/C). Frey J; Eberle S; Stahl C; Mazuet C; Popoff M; Schatzmann E; Gerber V; Dungu B; Straub R Equine Vet J; 2007 Nov; 39(6):516-20. PubMed ID: 18065309 [TBL] [Abstract][Full Text] [Related]
4. Immune response of horses to vaccination with the recombinant Hc domain of botulinum neurotoxin types C and D. Stahl C; Unger L; Mazuet C; Popoff M; Straub R; Frey J Vaccine; 2009 Sep; 27(41):5661-6. PubMed ID: 19646409 [TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of investigational recombinant botulinum vaccine, rBV A/B, in volunteers with pre-existing botulinum toxoid immunity. Khouri JM; Motter RN; Arnon SS Vaccine; 2018 Apr; 36(15):2041-2048. PubMed ID: 29475762 [TBL] [Abstract][Full Text] [Related]
6. Expression of HC subunits from Clostridium botulinum types C and D and their evaluation as candidate vaccine antigens in mice. Woodward LA; Arimitsu H; Hirst R; Oguma K Infect Immun; 2003 May; 71(5):2941-4. PubMed ID: 12704175 [TBL] [Abstract][Full Text] [Related]
7. Clinical Study of New Tetravalent (Type A, B, E, and F) Botulinum Toxoid Vaccine Derived from M Toxin in Japan. Torii Y; Sugimoto N; Kohda T; Kozaki S; Morokuma K; Horikawa Y; Ginnaga A; Yamamoto A; Takahashi M Jpn J Infect Dis; 2017 Jul; 70(4):423-429. PubMed ID: 28250257 [TBL] [Abstract][Full Text] [Related]
8. Phase II safety and immunogenicity study of type F botulinum toxoid in adult volunteers. Edelman R; Wasserman SS; Bodison SA; Perry JG; O'Donnoghue M; DeTolla LJ Vaccine; 2003 Oct; 21(27-30):4335-47. PubMed ID: 14505916 [TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial. Gorse GJ; Keitel W; Keyserling H; Taylor DN; Lock M; Alves K; Kenner J; Deans L; Gurwith M Vaccine; 2006 Aug; 24(33-34):5950-9. PubMed ID: 16797805 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of a recombinant Hc of Clostridium botulinum neurotoxin serotype F as an effective subunit vaccine. Yu YZ; Li N; Wang RL; Zhu HQ; Wang S; Yu WY; Sun ZW Clin Vaccine Immunol; 2008 Dec; 15(12):1819-23. PubMed ID: 18845829 [TBL] [Abstract][Full Text] [Related]
11. Production and immunogenic efficacy of botulinum tetravalent (A, B, E, F) toxoid. Torii Y; Tokumaru Y; Kawaguchi S; Izumi N; Maruyama S; Mukamoto M; Kozaki S; Takahashi M Vaccine; 2002 Jun; 20(19-20):2556-61. PubMed ID: 12057613 [TBL] [Abstract][Full Text] [Related]
12. Expression of Hc fragment from Clostridium botulinum neurotoxin serotype B in Escherichia coli and its use as a good immunogen. Gao YL; Gao S; Kang L; Nie C; Wang JL Hum Vaccin; 2010 Jun; 6(6):462-6. PubMed ID: 20519939 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of Clostridium botulinum types C and D toxoid vaccination in Danish cows. Krüger M; Skau M; Shehata AA; Schrödl W Anaerobe; 2013 Oct; 23():97-101. PubMed ID: 23831724 [TBL] [Abstract][Full Text] [Related]
14. Protective potential of recombinant non-purified botulinum neurotoxin serotypes C and D. Moreira C; da Cunha CE; Moreira GM; Mendonça M; Salvarani FM; Moreira ÂN; Conceição FR Anaerobe; 2016 Aug; 40():58-62. PubMed ID: 27236078 [TBL] [Abstract][Full Text] [Related]
15. [Serological study carried out in Cambodia during a tetanus vaccination in adults]. Schlumberger M; Yvonnet B; Que HV; Chhem DB; Saliou P; Le Tu TC; Glaziou P Bull Soc Pathol Exot; 2008 Feb; 101(1):36-42. PubMed ID: 18432006 [TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. Harro CD; Pang YY; Roden RB; Hildesheim A; Wang Z; Reynolds MJ; Mast TC; Robinson R; Murphy BR; Karron RA; Dillner J; Schiller JT; Lowy DR J Natl Cancer Inst; 2001 Feb; 93(4):284-92. PubMed ID: 11181775 [TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Kotloff KL; Wasserman SS; Losonsky GA; Thomas W; Nichols R; Edelman R; Bridwell M; Monath TP Infect Immun; 2001 Feb; 69(2):988-95. PubMed ID: 11159994 [TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of a tetravalent group B streptococcal polysaccharide vaccine in healthy adults. Kotloff KL; Fattom A; Basham L; Hawwari A; Harkonen S; Edelman R Vaccine; 1996 Apr; 14(5):446-50. PubMed ID: 8735558 [TBL] [Abstract][Full Text] [Related]
19. Cloning, expression and evaluation of a recombinant sub-unit vaccine against Clostridium botulinum type F toxin. Holley JL; Elmore M; Mauchline M; Minton N; Titball RW Vaccine; 2000 Sep; 19(2-3):288-97. PubMed ID: 10930684 [TBL] [Abstract][Full Text] [Related]
20. Variability of serum antibody responses of goat kids to a commercial Clostridium perfringens epsilon toxoid vaccine. Uzal FA; Bodero DA; Kelly WR; Nielsen K Vet Rec; 1998 Oct; 143(17):472-4. PubMed ID: 9829304 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]